
|Articles|September 10, 2003
Bisphosphonate shown to slow bone loss in advanced prostate cancer patients
An oral bisphosphonate may slow the development of symptomatic bone metastases and reduce the risk of death from this disease, new data show.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5












